FDA reviewers have identified high rates of ocular toxicity as GSK looks to place its blood cancer drug back on the market.

As supply chain disruption persists in pharma, global logistics providers with the expertise to overcome any challenge are essential.

Acumen has entered a partnership, option and licence agreement with JCR for developing an oligomer-targeted EBD for Alzheimer’s disease.

Otsuka Pharmaceutical has signed an agreement to acquire all assets related to Cantargia's early-clinical stage CAN10 programme.

Both AstraZeneca and MSD have tied lucrative licensing deals for two of LaNova’s oncology assets in recent years.